Literature DB >> 27168872

Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy.

Koichi Honda1, Masataka Seike1, Junya Oribe1, Mizuki Endo1, Mie Arakawa1, Hiroki Syo1, Masao Iwao1, Masanori Tokoro1, Junko Nishimura1, Tetsu Mori1, Tsutomu Yamashita1, Satoshi Fukuchi1, Toyokichi Muro1, Kazunari Murakami1.   

Abstract

AIM: To identify factors that influence long-term liver function following radiofrequency ablation (RFA) in patients with viral hepatitis-related hepatocellular carcinoma.
METHODS: A total of 123 patients with hepatitis B virus- or hepatitis C virus-related hepatocellular car-cinoma (HCC) (n = 12 and n = 111, respectively) were enrolled. Cumulative rates of worsening Child-Pugh (CP) scores (defined as a 2-point increase) were examined.
RESULTS: CP score worsening was confirmed in 22 patients over a mean follow-up period of 43.8 ± 26.3 mo. Multivariate analysis identified CP class, platelet count, and aspartate aminotransferase levels as signi-ficant predictors of a worsening CP score (P = 0.000, P = 0.011 and P = 0.024, respectively). In contrast, repeated RFA was not identified as a risk factor for liver function deterioration.
CONCLUSION: Long-term liver function following RFA was dependent on liver functional reserve, the degree of fibrosis present, and the activity of the hepatitis condition for this cohort. Therefore, in order to maintain liver function for an extended period following RFA, suppression of viral hepatitis activity is important even after the treatment of HCC.

Entities:  

Keywords:  Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Liver function; Radiofrequency ablation

Year:  2016        PMID: 27168872      PMCID: PMC4858624          DOI: 10.4254/wjh.v8.i13.597

Source DB:  PubMed          Journal:  World J Hepatol


  33 in total

1.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma.

Authors:  Hidekatsu Kuroda; Kazuhiro Kasai; Keisuke Kakisaka; Yuki Yasumi; Koujiro Kataoka; Akira Ushio; Yasuhiro Miyamoto; Kei Sawara; Kanta Oikawa; Koryo Kondo; Yoshiaki Miura; Ryujin Endo; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  Hepatol Res       Date:  2010-05       Impact factor: 4.288

3.  Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Hideo Yoshida; Haruhiko Yoshida; Eriko Goto; Takahisa Sato; Takamasa Ohki; Ryota Masuzaki; Ryosuke Tateishi; Tadashi Goto; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Hepatol Int       Date:  2007-09-26       Impact factor: 6.047

4.  Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

Authors:  Michael W Fried; Maria Buti; Gregory J Dore; Robert Flisiak; Peter Ferenci; Ira Jacobson; Patrick Marcellin; Michael Manns; Igor Nikitin; Fred Poordad; Morris Sherman; Stefan Zeuzem; Jane Scott; Leen Gilles; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Maria Beumont-Mauviel
Journal:  Hepatology       Date:  2013-10-11       Impact factor: 17.425

5.  Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study.

Authors:  Andrea Ruzzenente; Alfredo Guglielmi; Marco Sandri; Tommaso Campagnaro; Alessandro Valdegamberi; Simone Conci; Fabio Bagante; Gianni Turcato; Mirko D'Onofrio; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2011-11-18       Impact factor: 3.452

6.  Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma.

Authors:  T Seki; M Wakabayashi; T Nakagawa; T Itho; T Shiro; K Kunieda; M Sato; S Uchiyama; K Inoue
Journal:  Cancer       Date:  1994-08-01       Impact factor: 6.860

7.  Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Ji Hoon Kim; Joong-Won Park; Dong Wook Koh; Woo Jin Lee; Chang-Min Kim
Journal:  Liver Int       Date:  2008-07-24       Impact factor: 5.828

8.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

9.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

10.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

View more
  2 in total

1.  Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade.

Authors:  Hajime Matsushima; Yuko Takami; Tomoki Ryu; Munehiro Yoshitomi; Masaki Tateishi; Yoshiyuki Wada; Hideki Saitsu
Journal:  J Gastrointest Surg       Date:  2018-05-07       Impact factor: 3.452

2.  Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma.

Authors:  Toru Wakamatsu; Sadahisa Ogasawara; Tetsuhiro Chiba; Masayuki Yokoyama; Masanori Inoue; Naoya Kanogawa; Tomoko Saito; Eiichiro Suzuki; Yoshihiko Ooka; Akinobu Tawada; Osamu Yokosuka
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.